ClinicalTrials.gg
RecruitingNCT06941012VaMPiREUpdated Mar 2, 2026

Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution

An observational study in Parkinson Disease (PD), sponsored by Casa di Cura IGEA. Recruiting at 4 sites in 4 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Casa di Cura IGEA · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Parkinson Disease with a site in Greece — 5 open to participants now, 7 under way, none of them phase 3. Parkinson Disease · Greece.

Started
2025
the only one that year
Observational
8 of 20
4 open now
Registered
20th of 20
by date
Lead sponsor
1 of 20
Casa di Cura IGEA

Among the 20 studies in Parkinson Disease with a site in Greece, this one is the only one that started in 2025, is one of 8 observational ones, and was the 20th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 20 studies in Parkinson Disease with a site in Greece are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Parkinson Disease with a site in Greece, or all of them as a file.
02

Study summary

Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various bodily systems. Despite decades of research, understanding its onset and progression remains unclear, complicating early diagnosis and treatment. Recent advances in PD pathophysiology suggest promising treatments to slow disease progression, yet reversing cellular degeneration remains elusive. With novel therapies emerging, the need for early detection tools is urgent. However, validated biomarkers for PD diagnosis are lacking, relying on subjective scales like Hoehn and Yahr or costly medical imaging techniques. The accumulation of misfolded α-Synuclein (α-Syn) proteins in PD pathology has sparked interest, but defining diagnostic roles requires further investigation. Recent findings of α-Syn in neuronal-derived extracellular vesicles (NDEVs) from PD patients suggest a potential for novel diagnostic methods. Our proposed project, VαMPiRE, aims to conduct a longitudinal study involving 600 PD and 600 non-PD participants using a cluster-adjusted case-control methodology, to explore α-Syn isoforms and related biomarkers in NDEVs for early PD detection.

We plan to develop and validate an innovative in-vitro diagnostic (IVD) test capable of detecting PD's earliest stages and estimating disease prognosis and progression. Utilizing AI models to generate data analysis algorithms and collaboration with leading analytical laboratories and IVD manufacturers, we aim to ensure the reliability and feasibility of the developed prototype. Through consortium efforts, we envision licensing the generated intellectual property to drive the commercialization of our results.

Two round of blood sample extractions will be performed within a 24-month gap to PD participants and a single baseline for non-PD controls. All participants will be regularly followed up during this 24-month period to monitor disease evolution and treatment, and non-PD controls developing the disease will be part of a third cohort (expected to be around 24 subjects according to 4% incidence) that will confirm the sensitivity of the test in asymptomatic subjects. The unique aspect of the project is that we anticipate being able to detect theses 4% of non-PD participants that will go on to develop the disease, therefore demonstrating the value of these biomarkers to identify PD early.

The prototype will be validated for its discriminative capacity, using the first baseline set of PD and non-PD samples, and for its ability to detect the PD-progression comparing baseline and 24-months data plus blood samples.

Improved early screening could allow for 270,000 new cases of PD to be detected earlier, improve the disease management of 9.4 M people currently diagnosed of PD and avoid losing a total of 5.8 million disability adjusted life years (DALYs) by 2028 leading also the development of better treatments.

Read the detailed description

The VαMPiRE study (Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution) is a multicenter, longitudinal observational study in the context of European Grant Horizon Europe (101156370-2) and is designed to validate specific α-synuclein (α-Syn) isoforms and their post-translational modifications as biomarkers for the early detection and progression monitoring of Parkinson's disease (PD). The study addresses the critical unmet need for a cost-effective, non-invasive diagnostic method by combining innovative biochemical analyses, artificial intelligence (AI)-driven data models, and comprehensive clinical assessments. This effort aligns with emerging global priorities to enhance the early diagnosis and personalized treatment of neurodegenerative diseases.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

Keywords

  • α-Synuclein
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Recruitment will be conducted across five clinical sites, with each site contributing based on its recruitment capacity and resources.

PD patients and non-PD controls will be recruited among similar characteristics. A matched case-control approach will be implemented to meet the study's objectives. Matching will be used to control for potential confounding factors. By pairing or grouping participants with PD (cases) and those without PD (non-PD controls) based on shared characteristics-such as age, gender, geographic location, and relevant comorbidities (e.g., type 2 diabetes, hypertension, anemia, gastrointestinal dysfunction, etc.)-we aim to reduce bias and enhance statistical efficiency in adjusted analysis. As it will be difficult to exactly match all cases with equivalent controls, we will use the stratification to cluster PD and non-PD participants so comparative analysis can be performed between PD and non-PD equivalent clusters. Each time a participant is recruited into PD, he/

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • For PD subjects

      • PD diagnosis according to MDS-UPDRS criteria and Hoehn and Yahr scale between I-IV (MED ON) for PD subjects
      • Willing to participate. Participation is always voluntary.
      • Willing and able to provide written to participate in the study or having a legal representative responsible for signing; the participant (or the legal representative) must understand the purpose, methods, and all information regarding the study.
      • For non-PD subjects
      • Normal neurological examination findings.
      • Medical record (recent and remote medical history) available and reviewable by clinicians during the entire study period.
      • Willing and able to provide written informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

    • For PD and non-PD subjects

      • and severe cognitive decline and/or intellectual disability which can lead to impairment not caused by Parkinson's disease or any other disease that could better explain the patient's symptoms; The exclusion criteria involve neurological and neurodevelopmental disorders including disorders of the brain, spinal cord, peripheral nerve, and muscle (e.g. cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury).
      • Fever (Temperature 38.0 °C (tympanic)).
      • Acute infection (such as Flu, COVID-19) which could debilitate the patient and affect the data.
      • Individuals with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the pre-dose examinations (e.g. HepC, , TB).
      • Life-threatening co-existing disease with , which could lead to premature dropout.
      • Any other neurological or systemic conditions that could confound results.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Parkinson (PD)

    Other: Blood draw for the laboratory assessment

  • Non-PD controls

    Other: Blood draw for the laboratory assessment

Interventions

  • OtherBlood draw for the laboratory assessment

    Participants' clinical histories will be reviewed at T0 (baseline) and T1 (24 months). They will also undergo a clinical assessment at T0 and T1. The assessments will be tailored based on whether the participant belongs to the PD or non-PD group, as outlined below: • MDS-UPDRS + H\&Y: Used to evaluate the neurological domain, applied to the PD group. • BERG: Used to assess balance and performance, applied to both PD and non-PD groups. • CIRS-G: Used to evaluate comorbidities, applied to both PD and non-PD groups. • PD-CRS: Used to assess cognitive function, applied to the PD group. • MMSE (temporal and spatial orientation only): Used to assess cognitive function, applied to both PD and non-PD groups. • PDQ-8: Used to evaluate quality of life, applied to the PD group. • PD-CFRS: Used for functional assessment, applied to the PD group. • GDS: Used to assess depression, applied to both PD and non-PD groups. Blood samples will be collected at T0 and T1, with 20 mL drawn per participant.

    Also known as: Neurologic evaluation

06

What researchers measure

Primary outcomes

  1. Quantification of α-Synuclein Isoforms (-140, -126, -112, -98) and Their SUMOylated Forms in NDEVs from Blood Samples

    The primary outcome measure involves the quantification of α-synuclein (α-Syn) isoforms (-140, -126, -112, -98) and their SUMOylated forms in neuronal-derived extracellular vesicles (NDEVs) isolated from blood samples. Advanced biochemical techniques, including lateral flow immunoassay coupled with digital readers, are employed for precise quantification. AI-driven data analysis evaluates correlations between biomarker levels and Parkinson's Disease (PD) progression. Clinical Implications: This outcome aims to validate α-Syn biomarkers for early PD diagnosis, offering a non-invasive, cost-effective alternative to current methods like DaT imaging. Reliable identification of α-Syn isoforms could improve early intervention strategies, slow disease progression, and support personalized treatment plans. Additionally, it could provide insights into disease mechanisms, enhancing future therapeutic developments and enabling scalable, accessible diagnostic solutions globally.

    Time frame: Baseline (T0) and 24 months post-enrollment (T1).

Secondary outcomes

  1. Validation of AI-Generated predictive score for PD diagnosis

    Development and validation of artificial intelligence (AI)-powered diagnostic algorithms utilizing multivariate biomarker data, clinical assessments, and demographic variables. The AI model generates a predictive score correlating α-Syn biomarker levels with disease onset, progression, and treatment response. The validation process evaluates the model's sensitivity, specificity, and predictive accuracy for Parkinson's Disease diagnosis.

    Time frame: Baseline (T0), every 3 months through periodic surveys, and 24 months post-enrollment (T1).

Other outcomes

  1. Longitudinal Assessment of Patient-Reported Quality of Life (QoL) Using PDQ-8

    The Parkinson's Disease Questionnaire-8 (PDQ-8) is employed to assess changes in patient-reported quality of life (QoL) over the study period. It evaluates mobility, daily activities, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Scores are analyzed to monitor disease burden and its correlation with α-Syn biomarker levels.

    Time frame: Baseline (T0) and 24 months post-enrollment (T1).

07

Study locations

4 of 4 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) related to primary and secondary outcomes, demographic and baseline characteristics will be made available to qualified researchers upon reasonable request, following publication of study results. Data will be shared through appropriate data repositories and in compliance with applicable ethical and legal regulations. Via submission of a data access request to the study sponsor. Data will be shared through a secure institutional repository (e.g., Zenodo, ORE, EOSC).Key Exploitable Results will be disseminated through the Horizon Results Platform.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Starting 6 months after publication of the main study results. For a period of 5 years following publication.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2028, 42 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 42 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 23, 2025
StartActual
May 12, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Apr 30, 2029
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06941012
Lead sponsor
Casa di Cura IGEA
Collaborators
Asociación Parkinson Madrid, Aristotle University Of Thessaloniki, Institute of Psychiatry and Neurology, Warsaw, LINKCARE HEALTH SERVICES SL, ALMAWAVE SPA, European Brain Research Foundation
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
May 12, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Mar 2, 2026

Study contacts

Elda Judica, MD
Contact
e.judica@casadicuraigea.it
+39 0248593242
Annunziata Tramontano
Contact
a.tramontano@casadicuraigea.it
0039 0248593197
Marco Feligioni, PHD
study chair · EBRI-European Brain Research Insitute
Elda Judica, MD
principal investigator · Casa di Cura IGEA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion